RxDoctor Payments DataLook up a doctor →

Ramit Sharma, MD

Pulmonary Disease · Phoenix, AZNPI 1659374593

Payments from drug & device makers

$64,543in general payments, 2019–2025

Across 1,107 payments — averaging $58.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$19K
  • Bayer$16K
  • Mylan Specialty L.p.$12K
  • GSK$3K
  • AstraZeneca$3K
  • Genentech USA, Inc.$2K
  • plus $10K from 39 others

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
United Therapeutics Corporation47$19,446
Bayer35$15,660
Mylan Specialty L.p.71$12,218
GSK261$3,012
AstraZeneca103$2,863
Genentech USA, Inc.45$1,828
Actelion Pharmaceuticals US, Inc.78$1,253
Boehringer Ingelheim58$1,050
Grifols USA, LLC57$837
Sanofi46$752
Regeneron Healthcare Solutions, Inc.27$744
Paratek Pharmaceuticals, Inc.31$527
Mallinckrodt Hospital Products Inc.25$436
Philips North America LLC23$414
Amgen17$393
Sunovion Pharmaceuticals Inc.26$369
Takeda Pharmaceuticals U.S.A., Inc.15$296
Advanced Respiratory, Inc17$269
Electromed, Inc.23$258
Novartis14$238
Baxter Healthcare14$206
ANI Pharmaceuticals, Inc.10$167
Gilead8$156
Insmed, Inc.5$136
Teva Pharmaceuticals USA, Inc.6$103
Covis Pharma GmbH3$95
Pulmonx Corporation4$90
Circassia Inc.5$76
Sanofi-aventis U.S. LLC1$75
Nabriva Therapeutics, PLC5$73
Merck3$69
Mallinckrodt Enterprises LLC2$54
Qiagen, LLC1$48
Harmony Biosciences LLC2$44
Inspire Medical Systems, Inc.2$41
Cardiva Medical, Inc.2$39
Shire North American Group Inc2$38
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$33
Johnson & Johnson(2 entities)3$33
Shionogi Inc1$24
Inogen, Inc.1$23
Abbott1$17
Chiesi USA, Inc.1$16
Phadia US Inc.1$13
Vifor Pharma, Inc.1$13

How this compares

$64,543 in reported general payments places this provider in the 85th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona →

Medicare billing

Part B allowed, 2024
$210,317
Medicare patients
613
Services billed
2,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →